Phase 2 Study of Afatinib Plus Toripalimab in Previously Treated Recurrent or Metastasic Esophageal Squamous Cell Carcinoma With EGFR Overexpression or EGFR Amplification
Latest Information Update: 05 Jul 2023
At a glance
- Drugs Afatinib (Primary) ; Toripalimab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 11 Jul 2021 Planned initiation date changed from 1 May 2021 to 1 Jul 2021.
- 13 May 2021 New trial record